Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | MGMT | P16455 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8667325 | 0.80 | PNP (0.38) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL3694622 | 0.80 | — | — | |
| SCHEMBL5514289 | 0.74 | PNP (0.37) | PNPDPP4PDPK1GDAMGMT | |
| SCHEMBL6751932 | 0.70 | PNP (0.43) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL2983851 | 0.70 | PNP (0.49) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL27602647 | 0.70 | ATAD2 (0.49) | PNPDPP4PDPK1GDAHRH4 | |
| Water SCHEMBL9697811 | 0.69 | PNP (0.47) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL41788 | 0.69 | PNP (0.50) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL441798 | 0.68 | DPP4 (0.44) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL8886040 | 0.68 | PNP (0.49) | PNPDPP4PDPK1GDACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0726708-A1 | VIRUS ASSOCIATED MULTIPLE SCLEROSIS: TREATMENTS, PREVENTION AND DIAGNOSIS THEREOF | PATHOGENESIS CORPORATION (US) | 1996-08-21 | — | — | EP | claimed |
| WO-1995012313-A1 | VIRUS ASSOCIATED MULTIPLE SCLEROSIS: TREATMENTS, PREVENTION AND DIAGNOSIS THEREOF | PATHOGENESIS CORPORATION (US) | 1995-05-11 | — | — | WO | claimed |
| WO-2022002898-A1 | 6H-INDOLO(2,3-B)QUINOXALINE DERIVATIVES USEFUL IN THERAPY IN PARTICULAR IN A VIRUS INFECTION | VIRONOVA MEDICAL AB (SE) | 2022-01-06 | — | — | WO | disclosed |
| EP-2675457-B1 | PHARMACEUTICAL FORMULATION FOR TOPICAL ADMINISTRATION COMPRISING B220 | VIRONOVA HERPES AB (SE) | 2020-12-16 | — | — | EP | disclosed |
| US-10682370-B2 | Topical antiviral composition containing a local anesthetic and method of making the same | NAL PHARMACEUTICAL GROUP LIMITED (CN) | 2020-06-16 | — | — | US | disclosed |
| US-9789107-B2 | Pharmaceutical formulation comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-B)quinoxaline | VIRONOVA HERPES AB (SE) | 2017-10-17 | — | — | US | disclosed |
| EP-2282804-B1 | KIT FOR TOPICAL APPLICATION OF MEDICATION | NOVARTIS CONSUMER HEALTH SA (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20160031889-A1 | ANTIVIRAL INDOLO[2,3-B]QUINOXALINE | VIRONOVA HERPES AB (SE) | 2016-02-04 | — | — | US | disclosed |
| US-20160015731-A1 | A TOPICAL ANTIVIRAL COMPOSITION CONTAINING A LOCAL ANESTHETIC AND METHOD OF MAKING THE SAME | NAL PHARMACEUTICALS, LTD. (CN) | 2016-01-21 | — | — | US | disclosed |
| EP-2970292-A1 | ANTIVIRAL INDOLO[2,3-B]QUINOXALINE | Vironova Herpes AB (SE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150320746-A1 | PHARMACEUTICAL FORMULATION COMPRISING 2,3-DIMETHYL-6-(N,N-DIMETHYLAMINOETHYL)-6H-INDOLO-(2,3-B)QUINOXALINE | VIRONOVA HERPES AB (SE) | 2015-11-12 | — | — | US | disclosed |
| EP-1419803-A2 | Pharmaceutical composition for topical administration comprising an antiviral substance and a glucocorticoid | MEDIVIR AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| EP-0809498-B1 | PHARMACEUITICAL COMPOSITION FOR TOPICAL APPLICATION CONTAINING ACYCLOVIR AND HYDROCORTISONE | MEDIVIR AB (SE) | 2004-03-31 | — | — | EP | disclosed |
| EP-1296707-A4 | METHODS OF TREATING VIRAL DISEASES WITH IL-18 AND IL-18 COMBINATIONS | SMITHKLINE BEECHAM CORP (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030113292-A1 | Methods of treating viral diseases with il-18 and il-18 combinations | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-19 | — | — | US | disclosed |
| EP-1296707-A1 | METHODS OF TREATING VIRAL DISEASES WITH IL-18 AND IL-18 COMBINATIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6337324-B1 | VIRICIDES AND ANTIINFLAMMATORY AGENTS | MEDIVIR, AB (SE) | 2002-01-08 | — | — | US | disclosed |
| WO-2001093898-A1 | METHODS OF TREATING VIRAL DISEASES WITH IL-18 AND IL-18 COMBINATIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-0809498-A1 | NOVEL PHARMACEUTICAL COMBINATION | Astra Aktiebolag (SE) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996024355-A1 | NOVEL PHARMACEUTICAL COMBINATION | ASTRA AKTIEBOLAG (SE) | 1996-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320746-A1 | PHARMACEUTICAL FORMULATION COMPRISING 2,3-DIMETHYL-6-(N,N-DIMETHYLAMINOETHYL)-6H-INDOLO-(2,3-B)QUINOXALINE | NME2, S100A10, DSG1 | PNP 1025/4885DPP4 1688/4885PDPK1 1422/4885 |
| US-20160031889-A1 | ANTIVIRAL INDOLO[2,3-B]QUINOXALINE | IRF3, IFNG, IDO1 | PNP 167/4885DPP4 1364/4885PDPK1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.